A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

280

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

May 31, 2027

Conditions

Uncontrolled Hypertension

Interventions

DRUG

RTN-001

A potent and selective PDE5 inhibitor.

DRUG

Matching placebo control

The reference/comparator product is a matching placebo tablet with similar appearance and weight as the RTN-001 oral tablet.

All Listed Sponsors

lead

Retension Pharmaceuticals. Inc.

INDUSTRY

NCT07142356 - A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension | Biotech Hunter | Biotech Hunter